- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03919045
Saline Injections for Prophylactic Treatment of Chronic Migraine
Saline Injections for Prophylactic Treatment of Chronic Migraine - a Randomized Controlled Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Borås, Sweden
- Rehabilitation clinic, Southern Älvsborg Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participants must meet the diagnostic criteria for chronic migraine (headache that have occurred on at least 15 days per month, for at least three months. At least eight of the headache episodes must be typical for migraine).
- Participants must be able to understand and give informed consent to participate in the study.
- Participants must be aged 18-65 years.
Exclusion Criteria:
- Participants must not suffer from other medical conditions that may affect the outcome of the study, including Horton's headache, temporal arteritis, trigeminal neuralgia, chronic paroxysmal hemi-crania, atypical facial pain and headache of unknown cause.
- Participants must not have medical conditions that require use of drugs that can affect the headache pattern (for example rheumatic disorders).
- Participants must not suffer from malignant diseases.
- Participants must not plan to make changes to existing prophylactic headache medication during the study. Patients may, if already on treatment, choose to continue this throughout the course of the study, or choose to stop the prophylactic treatment at least one week before the start of the baseline period.
- Participants must not have an ongoing patient-doctor contact with the physician giving the injections.
- Participants must not have an ongoing patient-doctor contact with the monitor of the study.
- Participants must not have received injection therapy in the face, head or neck muscles (medical or cosmetic) less than three months before the start of the study, nor should they plan such treatment during the course of the study.
- Participants must not be pregnant or plan pregnancy during the course of the study.
- Participants must not breastfeed or plan to do so during the study.
- Participants must not have any contraindications to injection therapy (such as disease with increased bleeding tendency or treatment with certain types of blood thinners).
- Participants must have no difficulty understanding or making themselves understood in Swedish.
- Participants must be able to fill out the headache diary and questionnaires.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sodium chloride injection
Sodium chloride 9mg/ml by injection
|
Half of the patients will be randomized to saline injections into the neck and head muscles
Other Names:
|
Placebo Comparator: Needle sting
Brief needle stings without injection
|
Half of the group will be treated with needle stings without injections
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in number of Days with headache
Time Frame: change between baseline 28 day period prior injection1 and 28 day period ending study
|
A headache day is defined as: 1) a day with headache ≥ 4 hours or 2) a day with headache of any duration, where the headache is relieved with acute headache medication (AHM) By AHM is meant a drug that is taken when needed for the purpose of relieving headaches, including any of the following:
The primary efficacy measure is the change between the baseline 28-day period (4 weeks prior injection 1) and the corresponding period during follow-up, i.e. the 28-day period ending the study. a secondary efficacy measure is the change between the baseline and the 28-day period preceding the second injection. |
change between baseline 28 day period prior injection1 and 28 day period ending study
|
Change in number of Days with headache
Time Frame: change between baseline and the 28-day period preceding the second injection
|
A headache day is defined as: 1) a day with headache ≥ 4 hours or 2) a day with headache of any duration, where the headache is relieved with acute headache medication. By AHM is meant a drug that is taken when needed for the purpose of relieving headaches, including any of the following:
The primary efficacy measure is the change between the baseline 28-day period (4 weeks prior injection 1) and the corresponding period during follow-up, i.e. the 28-day period ending the study. a secondary efficacy measure is the change between the baseline and the 28-day period preceding the second injection. |
change between baseline and the 28-day period preceding the second injection
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Days with moderate or severe headache
Time Frame: change between baseline 28 day period prior injection1 and 28 day period ending study
|
A headache day with moderate or severe intensity is defined as: 1) a day with headache ≥ 4 hours and with a peak of moderate or severe intensity or 2) a day with headache of any duration or intensity, where the headache is relieved with AHM.
The primary efficacy measure is the change between the baseline 28-day period (4 weeks prior injection 1) and the corresponding period during follow-up, i.e. the 28-day period ending the study.
a secondary efficacy measure is the change between the baseline and the 28-day period preceding the second injection.
|
change between baseline 28 day period prior injection1 and 28 day period ending study
|
Number of Days with moderate or severe headache
Time Frame: change between baseline and the 28-day period preceding the second injection
|
A headache day with moderate or severe intensity is defined as: 1) a day with headache ≥ 4 hours and with a peak of moderate or severe intensity or 2) a day with headache of any duration or intensity, where the headache is relieved with AHM.
The primary efficacy measure is the change between the baseline 28-day period (4 weeks prior injection 1) and the corresponding period during follow-up, i.e. the 28-day period ending the study.
a secondary efficacy measure is the change between the baseline and the 28-day period preceding the second injection.
|
change between baseline and the 28-day period preceding the second injection
|
Number of days with acute headache medication
Time Frame: change between baseline 28 day period prior injection1 and 28 day period ending study
|
Number of days the respondent stated that AHM has been taken.The primary efficacy measure is the change between the baseline 28-day period (4 weeks prior injection 1) and the corresponding period during follow-up, i.e. the 28-day period ending the study.
a secondary efficacy measure is the change between the baseline and the 28-day period preceding the second injection.
|
change between baseline 28 day period prior injection1 and 28 day period ending study
|
Number of days with acute headache medication
Time Frame: change between baseline and the 28-day period preceding the second injection
|
Number of days the respondent stated that AHM has been taken.The primary efficacy measure is the change between the baseline 28-day period (4 weeks prior injection 1) and the corresponding period during follow-up, i.e. the 28-day period ending the study.
a secondary efficacy measure is the change between the baseline and the 28-day period preceding the second injection.
|
change between baseline and the 28-day period preceding the second injection
|
Number of days with acute headache medication that requires prescription
Time Frame: change between baseline 28 day period prior injection1 and 28 day period ending study
|
Number of days the respondent stated that he or she has taken acute headache medication that require prescription, ie all drugs in the list in primary outcome above that require prescription by a doctor.The primary efficacy measure is the change between the baseline 28-day period (4 weeks prior injection 1) and the corresponding period during follow-up, i.e. the 28-day period ending the study.
a secondary efficacy measure is the change between the baseline and the 28-day period preceding the second injection.
|
change between baseline 28 day period prior injection1 and 28 day period ending study
|
Number of days with acute headache medication that requires prescription
Time Frame: change between baseline and the 28-day period preceding the second injection
|
Number of days the respondent stated that he or she has taken acute headache medication that require prescription, ie all drugs in the list in primary outcome above that require prescription by a doctor.The primary efficacy measure is the change between the baseline 28-day period (4 weeks prior injection 1) and the corresponding period during follow-up, i.e. the 28-day period ending the study.
a secondary efficacy measure is the change between the baseline and the 28-day period preceding the second injection.
|
change between baseline and the 28-day period preceding the second injection
|
Change in outcome of disease-specific quality of Life: Migraine-specific Quality of Life Questionnaire (MSQ v2.1)
Time Frame: Change between baseline and 12 weeks after second injection
|
Change in Migraine-specific Quality of Life Questionnaire (MSQ v2.1)
|
Change between baseline and 12 weeks after second injection
|
Change in outcome of disease-specific implications: Headache Impact Test (HIT-6)
Time Frame: Change between baseline and 12 weeks after second injection
|
Change in Headache Impact Test (HIT-6)
|
Change between baseline and 12 weeks after second injection
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Malin Kim, MD, Rehabilitation clinic, Southern Älvsborg Hospital
Publications and helpful links
General Publications
- Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF; PREEMPT Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010 Jun;50(6):921-36. doi: 10.1111/j.1526-4610.2010.01678.x. Epub 2010 May 7.
- Cole JC, Lin P, Rupnow MF. Validation of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ v. 2.1) for patients undergoing prophylactic migraine treatment. Qual Life Res. 2007 Sep;16(7):1231-7. doi: 10.1007/s11136-007-9217-1. Epub 2007 Apr 28.
- Freitag FG, Diamond S, Diamond M, Urban G. Botulinum Toxin Type A in the treatment of chronic migraine without medication overuse. Headache. 2008 Feb;48(2):201-9. doi: 10.1111/j.1526-4610.2007.00963.x. Epub 2007 Nov 28.
- Gandek B, Alacoque J, Uzun V, Andrew-Hobbs M, Davis K. Translating the Short-Form Headache Impact Test (HIT-6) in 27 countries: methodological and conceptual issues. Qual Life Res. 2003 Dec;12(8):975-9. doi: 10.1023/a:1026171315263.
- Smelt AF, Assendelft WJ, Terwee CB, Ferrari MD, Blom JW. What is a clinically relevant change on the HIT-6 questionnaire? An estimation in a primary-care population of migraine patients. Cephalalgia. 2014 Jan;34(1):29-36. doi: 10.1177/0333102413497599. Epub 2013 Jul 10.
- Goadsby PJ. Migraine pathophysiology. Headache. 2005 Apr;45 Suppl 1:S14-24. doi: 10.1111/j.1526-4610.2005.4501003.x.
- Kim M, Danielsson A, Ekelund A-C, Kemppainen E, Sjögren P, Svanberg T, Szalo G,Samuelsson O. Title:Botulinum toxin type A for Prophylactic Treatment of Chronic Migraine [Botulinum toxin typ Asom profylaktisk behandling av kronisk migrän]. Göteborg: Västra Götalandsregionen, SahlgrenskaUniversitetssjukhuset, HTA-centrum; 2014. Regional activity-based HTA 2014:70
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Migraine1
- 2018-003868-32 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Migraine
-
Tonix Pharmaceuticals, Inc.PremierCompletedChronic Migraine | Chronic Migraine, Headache | Chronic Migraine Without Aura | Aura MigraineUnited States
-
AbbVieActive, not recruitingChronic Migraine | Episodic MigraineUnited States, Canada, Czechia, Denmark, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Poland, Spain, Taiwan, United Kingdom
-
AbbVieActive, not recruitingChronic Migraine | Episodic MigraineJapan
-
Assiut UniversityRecruitingChronic Migraine | Chronic Migraine, HeadacheEgypt
-
AbbVieRecruiting
-
Universidad de ZaragozaUniversidad San Jorge; Hospital Clínico Universitario Lozano BlesaRecruiting
-
Taichung Veterans General HospitalCompleted
-
Austrian Migraine Registry CollaborationMedical University of Vienna; Medical University Innsbruck; Austrian Headache...RecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With Aura | Episodic MigraineAustria
-
University of FlorenceAzienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaboratorsRecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With AuraItaly
-
University of FlorenceAzienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaboratorsRecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With AuraItaly
Clinical Trials on Saline injection
-
The Catholic University of KoreaCompleted
-
Aalborg UniversityThe Danish Rheumatism AssociationCompleted
-
National Taiwan University HospitalRecruitingOsteoarthritis (OA) of the KneeTaiwan
-
New York Medical CollegeCompletedWrinkle | Nasolabial Fold | Skin Rejuvenation | Skin QualityUnited States
-
Odense University HospitalCompleted
-
Kaiser PermanenteTerminatedLateral Epicondylitis | Tennis ElbowUnited States
-
The Jerzy Kukuczka Academy of Physical Education...University of LuebeckCompleted
-
MiMedx Group, Inc.Completed
-
Singapore General HospitalNot yet recruitingLateral Epicondylitis, Unspecified Elbow